公开(公告)号：US20160228980A1

公开(公告)日：2016-08-11

申请号：US15021930

申请日：2014-09-12

Applicant: UNIVERSITÄT STUTTGART

Inventor： Martin WERZ ,  Max HOSSFELD ,  Oliver VOLZ

IPC: B23K20/12 ,  B23K20/227

CPC classification number: B23K20/125 ,  B23K20/1255 ,  B23K20/227 ,  B23K20/2275 ,  B23K33/002

Abstract: Provided is a method and tool for butt welding a first material piece of metal to a second material piece of metal at opposed longitudinal edges. The second material piece has a greater material thickness than the first material piece. The first material piece has a higher tensile strength and/or a higher melting temperature and/or a higher yield strength and/or a higher modulus of elasticity than the second material piece. A thickened longitudinal edge is provided at the first material piece. The thickening of the longitudinal edge is at least partly produced by at least simple folding, beading or winding of the first material piece or at least partly by beveling the first material piece at its edge. The two material pieces are friction-stir welded at their front along the opposed longitudinal edges.

Abstract translation: 提供了一种用于将第一材料片对接到在相对的纵向边缘处的金属的第二材料片的方法和工具。 第二材料件具有比第一材料件更大的材料厚度。 第一材料片具有比第二材料片更高的拉伸强度和/或更高的熔化温度和/或更高的屈服强度和/或更高的弹性模量。 在第一材料件处设置加厚的纵向边缘。 纵向边缘的增厚至少部分地通过至少简单的第一材料片的折叠，卷边或卷绕部分产生，或至少部分地通过在其边缘处使第一材料片倒角。 两个材料片沿其相对的纵向边缘在其前部摩擦搅拌焊接。

公开(公告)号：US20140249343A1

公开(公告)日：2014-09-04

申请号：US14118214

申请日：2012-06-28

Applicant: UNIVERSITÄT STUTTGART ,  STAMICARBON B.V. ACTING UNDER THE NAME OF MT INNOVATION CENTER

Inventor： Yvonne Traa ,  Daniel Geiss

IPC: C07C2/66

CPC classification number: C07C2/66 ,  B01J29/068 ,  B01J29/44 ,  B01J37/08 ,  B01J37/18 ,  B01J2229/186 ,  C07C2/76 ,  C07C2529/06 ,  C07C2529/40 ,  C07C2529/44 ,  C07C2529/48 ,  C07C2529/65 ,  C07C2529/67 ,  C07C2529/69 ,  C07C2529/85 ,  C07C2531/22 ,  C07C15/02 ,  C07C15/27

Abstract: Disclosed is a process for the direct alkylation of aromatic compounds with alkanes. To this end a judicious catalyst combination is provided. The composition comprises palladium as a catalytically active metal, and zinc as a promoter, or a metal such as tin having a comparable promoting action. The metals are contained in a zeolite support, or a similar support of a metal organic framework type or a silico alumino phosphate type.

Abstract translation: 公开了用烷烃直接烷基化芳族化合物的方法。 为此，提供了明智的催化剂组合。 组合物包含作为催化活性金属的钯，作为助催化剂的锌，或具有可比较的促进作用的金属如锡。 金属包含在沸石载体中，或类似的金属有机骨架型或硅铝型磷酸盐载体。

公开(公告)号：US12062994B2

公开(公告)日：2024-08-13

申请号：US17381443

申请日：2021-07-21

Applicant: UNIVERSITÄT STUTTGART

Inventor： David Maier ,  Marco Zimmer ,  Nejila Parspour

IPC: H02P6/15 ,  H02J50/10 ,  H02M7/217 ,  H02P9/12 ,  H02P25/022

CPC classification number: H02M7/217 ,  H02J50/10 ,  H02P25/022

Abstract: The present invention relates to a circuit arrangement having an active rectifier circuit, in particular on a secondary side of an inductive energy transmission path. The circuit arrangement has a half or full bridge of power transistors for rectifying an AC voltage induced in an input inductor of the circuit arrangement. The power transistors are connected to the input inductor in such a way that an auxiliary voltage is split off from the induced AC voltage for switching the power transistors. As a result, even large currents, which result in a low output voltage, can be transmitted without endangering the operation of the rectifier circuit.

公开(公告)号：US20240194367A1

公开(公告)日：2024-06-13

申请号：US18530288

申请日：2023-12-06

Applicant: Universität Stuttgart ,  Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.

Inventor： Florian MEINERT ,  Philipp ILZHOEFER ,  Tilman PFAU ,  Martin TRAUB ,  Martin ADAMS ,  Hans-Dieter HOFFMANN

IPC: G21K1/00 ,  G21K1/06

CPC classification number: G21K1/003 ,  G21K1/06 ,  G21K2201/067

Abstract: The present invention relates to a device (10) for generating optical tweezers comprising a laser beam source (11) for generating a laser beam (12) and at least one acousto-optic deflector (13) for generating an array (15) of partial beams (14) of the laser beam (12), wherein the array (15) comprises rows (15c). The device (10) further comprises a stepped mirror unit (16) comprising at least a first stepped mirror (25) for reducing a row distance (15d) of the partial beams (14) of the array (15), wherein the first stepped mirror (25) comprises mirrors (30), a stepped distance (25a) between adjacent mirrors (30) and a stepped height (25b).

公开(公告)号：US11851489B2

公开(公告)日：2023-12-26

申请号：US16615536

申请日：2018-06-01

Applicant: UNIVERSITÄT STUTTGART

Inventor： Fabian Richter ,  Oliver Seifert ,  Roland Kontermann

IPC: C07K16/28 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  A61K38/00

CPC classification number: C07K16/2809 ,  C07K16/2878 ,  C07K16/30 ,  C07K16/32 ,  C07K16/40 ,  A61K38/00 ,  C07K2317/31 ,  C07K2317/522 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/528 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/94

Abstract: The present invention provides a protein complex comprising heterodimerizing regions HRI and HRII, each comprised of antiparallel β-strands and intervening regions wherein HRI and HRII are each interspersed fusion proteins of two human constant regions of an immunoglobulin or immunoglobulin-like proteins. The present invention also provides nucleic acid molecules comprising a sequence encoding said protein complexes and vectors comprising the nucleic acid. The present invention also provides the protein complex, the nucleic acid and the vector for use as a medicament. The present invention further provides a method of determining the amino acid sequence of HRI and/or of the amino acid sequence of HRII. The present invention also provides a method of producing amino acid chains of HRI and/or amino acid chains of HRII. The present invention further provides the protein complex for use in the N prophylaxis, treatment or diagnosis of a disorder or a disease.

公开(公告)号：US20230182929A1

公开(公告)日：2023-06-15

申请号：US18077291

申请日：2022-12-08

Applicant: Universität Stuttgart

Inventor： Francesco ROMANO ,  Yung-An CHAN ,  Georg HERDRICH ,  Stefanos FASOULAS

IPC: B64G1/40 ,  H05H1/54 ,  G01R33/34

CPC classification number: B64G1/405 ,  H05H1/54 ,  G01R33/34076 ,  H05H2245/00 ,  B33Y80/00

Abstract: A plasma thruster comprises a cylindrical discharge channel (1), an injector (4), a RF antenna surrounding the discharge channel (1) and a device (3) for generating an axial static magnetic field in the discharge channel (1). The RF antenna is a cylindrical birdcage antenna (2) formed of several electrically conductive parallel legs (10) connected by two end rings (11) including capacitors (12) between adjacent legs (10) in each case. The two end rings (11) with the capacitors (12) are formed on two printed circuit boards (14) to which the legs (10) are attached, said printed circuit boards (14) having a through opening for the discharge channel (1). The antenna maximizes electrical coupling efficiency and provides resulting electromagnetic fields for quasi-neutral plasma acceleration along with the magnetic field effect provided by the externally applied magnetic field. This plasma thruster allows an easy upscaling or downscaling due to the printed circuit boards and is particularly suitable for low power applications like propulsion for smaller spacecrafts or satellites.

公开(公告)号：US20210395323A1

公开(公告)日：2021-12-23

申请号：US17465186

申请日：2021-09-02

Applicant: UNIVERSITÄT STUTTGART

Inventor： Roman FISCHER ,  Roland KONTERMANN ,  Klaus PFIZENMAIER ,  Martin SIEGEMUND

IPC: C07K14/525

Abstract: The present invention relates to a tumor necrosis factor receptor (TNFR) binding protein complex comprising 12 or more N protein ligands (PLs) that specifically bind to the extracellular part of the same TNFR. Preferably, the TNFR binding protein complex binds to the extracellular part of TNFR2. Preferably, the TNFR binding protein complex of the present invention further comprises a two or more polymerization domains (PD).

公开(公告)号：US11008402B2

公开(公告)日：2021-05-18

申请号：US16326864

申请日：2017-09-15

Applicant: UNIVERSITÄT STUTTGART

Inventor： Roland Kontermann ,  Lisa Schmitt ,  Meike Hutt ,  Oliver Seifert ,  Monilola Olayioye ,  Michael Hust ,  Stefan Dübel ,  Jonas Zantow

IPC: A61K39/00 ,  C07K16/32 ,  C07K16/28 ,  C07K16/30 ,  A61P35/00 ,  A61K39/395

Abstract: The invention provides an antigen-binding protein that specifically binds to a conformational epitope formed by domain III & IV of human epidermal growth factor receptor 3 (HER3) and antigen-binding proteins which compete therewith for binding, as well as fusion protein or conjugate comprising these. The invention also provides nucleic acid molecule comprising a sequence encoding said antigen binding proteins, vectors comprising the nucleic acid, and cells and pharmaceuticals comprising the antigen binding protein, the fusion protein, the nucleic acid, or the vector. The invention also provides the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical for use as a medicament. The invention further provides a method of inhibiting tumor growth or treating cancer, comprising administering a therapeutically effective amount of the antigen binding protein, the fusion protein or conjugate, the nucleic acid, the vector, the cell, or the pharmaceutical.

公开(公告)号：US20210002376A1

公开(公告)日：2021-01-07

申请号：US16982714

申请日：2018-03-22

Applicant: UNIVERSITÄT STUTTGART

Inventor： Oliver SEIFERT ,  Roland KONTERMANN ,  Fabian RICHTER

IPC: C07K16/28 ,  C07K16/32 ,  A61P35/00

Abstract: The present invention relates to a modular multivalent antigen-binding protein complex, use of the antigen-binding protein complex in medicine and use of the antigen-binding protein complex in the prophylaxis, treatment or diagnosis of a disorder or disease.

公开(公告)号：US10689452B2

公开(公告)日：2020-06-23

申请号：US16091456

申请日：2017-04-04

Applicant: UNIVERSITÄT STUTTGART ,  BALIOPHARM AG

Inventor： Roland Kontermann ,  Klaus Pfizenmaier ,  Fabian Richter ,  Kirstin Zettlitz ,  Peter Scheurich ,  Andreas Herrmann

IPC: C07K16/28 ,  A61P37/06

Abstract: The invention provides for an inhibitor of the huTNFRI receptor which is a human or humanized antibody construct that monovalently recognizes huTNFRI through an antigen-binding moiety, which is characterized by specific CDR sequences, a pharmaceutical preparation thereof, method of producing the inhibitor and the medical use of the inhibitor.